Medical Australia (ASX:MLA) has secured an exclusive licensing agreement from Nanofiber Veterinary for distribution of NanoWhiskersV™ and NanoCareV™ product lines in Australia, Japan, and the United States.
The innovative product lines provide a valuable adjunct to MediVet’s already established adipose-derived stem cell technology to further enhance the treatment of a variety of degenerative conditions and diseases in animals including osteoarthritis.
The Nanofiber technology provides a supportive framework and an optimal healing environment for stem cells to proliferate, differentiate and regenerate damaged tissues.
NanoWhiskersV™ use injectable FDA-approved polymer fibres to increase cellular localisation in the area of ailment to regenerate joints.
It assists stem cell binding to the scaffolding matrix, and guides cellular growth causing cells to replicate and differentiate to form functional tissues.
NanoCareV™ provides expedited healing of all types of wounds in animals. It is a durable, bio-stable mesh with a temporary skin substitute that is placed directly over a wound followed by a series of Platelet Rich Plasma.
The technology from Nanofiber Solutions vastly increases the scope of application of MediVet’s Stem Cell Technology and for the treatment of wounds, joint injury and joint degeneration in both small animal and equine patients on a global scale providing a platform for growth.
MLA will now collaborate with Nanofiber Veterinary to continue ongoing research projects to achieve increased efficacy, continued learning and promote hands on access to veterinary regenerative medicine.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China